This 2022 systematic review evaluated the benefits and harms of systemic hormone therapy (HT) for the primary prevention of chronic conditions in postmenopausal individuals. Analyzing 20 trials (n=39,145) and 3 cohort studies (n=1,155,410), the review found that while HT reduced risks of diabetes and fractures, it increased risks of gallbladder